Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05211323 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
A Phase 2 study of Stage IV Liver Cancer and Combined Hepatocellular Carcinoma and Cholangiocarcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 20
- Study locations
NCT05211323 is a Phase 2 study of Stage IV Liver Cancer and Combined Hepatocellular Carcinoma and Cholangiocarcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 88 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT05211323, a Phase 2 study of Stage IV Liver Cancer and Combined Hepatocellular Carcinoma and Cholangiocarcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bevacizumab and atezolizumab with chemotherapy may kill more tumor cells in patients liver cancer than chemotherapy and atezolizumab.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- BIOLOGICAL Atezolizumab
- DRUG Cisplatin
- BIOLOGICAL Bevacizumab
Study Locations (20)
California
- Sutter Auburn Faith Hospital - Auburn
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Palo Alto Medical Foundation-Fremont - Fremont
- Memorial Medical Center - Modesto
- Palo Alto Medical Foundation-Camino Division - Mountain View
- Palo Alto Medical Foundation Health Care - Palo Alto
- Sutter Roseville Medical Center - Roseville
- Sutter Medical Center Sacramento - Sacramento
- California Pacific Medical Center-Pacific Campus - San Francisco
- Palo Alto Medical Foundation-Santa Cruz - Santa Cruz
- Palo Alto Medical Foundation-Sunnyvale - Sunnyvale
- Sutter Solano Medical Center/Cancer Center - Vallejo
Illinois
- Carle at The Riverfront - Danville
- Carle Physician Group-Effingham - Effingham
- Carle Physician Group-Mattoon/Charleston - Mattoon
- Carle Cancer Center - Urbana
- The Carle Foundation Hospital - Urbana
Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic - Ankeny
- Iowa Methodist Medical Center - Des Moines
Indiana
- Memorial Hospital of South Bend - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05211323
The ClinicalTrials.gov registry entry for NCT05211323 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IV Liver Cancer appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05211323 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, Iowa.
Frequently Asked Questions
What is clinical trial NCT05211323 about?
NCT05211323 is a clinical study titled "A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer". This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started ...
What is the current status of trial NCT05211323?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2022-12-07. Estimated completion is 2026-06-30.
What conditions does trial NCT05211323 study?
This clinical trial studies the following conditions: Stage IV Liver Cancer, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer.
What interventions are being tested in trial NCT05211323?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Atezolizumab (BIOLOGICAL), Cisplatin (DRUG), Bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05211323?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05211323 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Stage IV Liver Cancer
All registered trials for this condition
Combined Hepatocellular Carcinoma and Cholangiocarcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.